Recurrence-free survival as a putative surrogate for overall survival in phase III trials of curative-intent treatment of colorectal liver metastases: Systematic review

10.1200/JCO.2003.08.156

Langer B, Bleiberg H, Labianca R, Shepard L, Nitti D, Marsoni S, Tu D, Sargeant A, Fields A. Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Proc Am Soc Clin Oncol 2002;21:Abstract 592.

10.1016/s0140-6736(08)60455-9

10.1200/jco.2006.06.8353

10.1245/s10434-014-4354-6

10.1136/eb-2013-101700

10.1136/eb-2013-101699

10.1016/s1470-2045(14)70105-6

10.1093/annonc/mdp236

Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn’t. BMJ 1996;312:71-72.

10.2106/JBJS.L.00193

Fireman BH, Fehrenbacher L, Gruskin EP, Ray GT. Cost of care for patients in cancer clinical trials. J Natl Cancer Inst 2000;92:136-142.

10.1056/NEJMp1400104

10.1200/JCO.2006.08.1935

10.1158/1078-0432.CCR-12-1515

10.1200/JCO.2006.10.4323

10.1016/s1470-2045(13)70447-9

Adam R, Bismuth H, Castaing D, Waechter F, Navarro F, Abascal A, Majno P, Engerran L. Repeat hepatectomy for colorectal liver metastases. Ann Surg 1997;225:51-60; discussion 60-62.

10.1002/bjs.9088

10.1038/nm.3967